A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

I8F-MC-GPIL -

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide/(GIP/GLP-1 RA agonist) in participants with type 2 diabetes (T2D).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 diabetes
What the trial is testing?
LY3298176
Could I receive a Placebo?
No
Enrollment Goal
152
Trial Dates
Mar 8, 2023 - Oct 31, 2023
How long will I be in the trial?
The study will last approximately 15 weeks and up to 6 visits.
Trial Phase
IV

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have Type 2 diabetes

  • Must be overweight

  • Not be taking diabetes medications 3 months before entering the study

Participants Must Not:

  • Have Type 1 diabetes

  • Have history of diabetic eye diseases

  • Have heart disease or stroke

  • Have had an episode of ketoacidosis

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources